These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30982394)

  • 21. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.
    Yuan D; Rode F; Cao Y
    AAPS J; 2018 Mar; 20(3):48. PubMed ID: 29541870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
    Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
    J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
    Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
    MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia.
    McCarthy KM; Yoong Y; Simister NE
    J Cell Sci; 2000 Apr; 113 ( Pt 7)():1277-85. PubMed ID: 10704378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target-independent variable region mediated effects on antibody clearance can be FcRn independent.
    Kelly RL; Yu Y; Sun T; Caffry I; Lynaugh H; Brown M; Jain T; Xu Y; Wittrup KD
    MAbs; 2016 Oct; 8(7):1269-1275. PubMed ID: 27610650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
    Maas BM; Cao Y
    MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
    Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
    MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
    Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
    Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor.
    Tesar DB; Tiangco NE; Bjorkman PJ
    Traffic; 2006 Sep; 7(9):1127-42. PubMed ID: 17004319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of nanobodies that target human neonatal Fc receptor.
    Andersen JT; Gonzalez-Pajuelo M; Foss S; Landsverk OJ; Pinto D; Szyroki A; de Haard HJ; Saunders M; Vanlandschoot P; Sandlie I
    Sci Rep; 2013; 3():1118. PubMed ID: 23346375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
    Cines DB; Zaitsev S; Rauova L; Rux AH; Stepanova V; Krishnaswamy S; Sarkar A; Kowalska MA; Zhao G; Mast AE; Blumberg LJ; McCrae KR; Poncz M; Hubbard JJ; Pyzik M; Blumberg RS
    Blood; 2020 Jun; 135(23):2085-2093. PubMed ID: 32187355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.
    Ramdani Y; Lamamy J; Watier H; Gouilleux-Gruart V
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies directed against human FcRn and their applications.
    Christianson GJ; Sun VZ; Akilesh S; Pesavento E; Proetzel G; Roopenian DC
    MAbs; 2012; 4(2):208-16. PubMed ID: 22453095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions.
    Sockolosky JT; Tiffany MR; Szoka FC
    Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16095-100. PubMed ID: 22991460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier.
    Caram-Salas N; Boileau E; Farrington GK; Garber E; Brunette E; Abulrob A; Stanimirovic D
    Methods Mol Biol; 2011; 763():383-401. PubMed ID: 21874466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacokinetics (PK) of mAbs].
    Paintaud G
    Med Sci (Paris); 2009 Dec; 25(12):1057-62. PubMed ID: 20035679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
    Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
    MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.
    Challa DK; Velmurugan R; Ober RJ; Sally Ward E
    Curr Top Microbiol Immunol; 2014; 382():249-72. PubMed ID: 25116104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.